Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 3, 2013, Pages 253-257

  Yared, Jean ^a   Kimball, Amy ^a   Baer, Maria R ^a   Bahrain, Huzefa ^b   Auerbach, Michael ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b Auerbach Hematology and Oncology   (United States)

Author keywords

Follicular lymphoma; Indolent lymphoma; Prolonged rituximab maintenance; Rituximab; Rituximab maintenance

Indexed keywords

ANTIBIOTIC AGENT; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INDUCTION CHEMOTHERAPY; INFECTION; LUNG ABSCESS; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84877733170     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.12.011     Document Type: Article

References (22)

1. G. Salles, J.F. Seymour, F. Offner Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Lancet 377 2011 42 51
2. A. Ayoola, M. Terrell, H. Bahrain, P. Ford, M. Auerbach Experience with maintenance rituximab after chemotherapy in patients with low-grade lymphoma Community Oncology 7 2010 414 417
3. B.D. Cheson, S.J. Horning, B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
4. B.D. Cheson, B. Pfistner, M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586 (Pubitemid 350002966)
5. K.M. Ardeshna, W. Qian, P. Smith An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a) A preliminary analysis ASH Annual Meeting Abstracts 116 2010 6
6. H. Hochster, E. Weller, R.D. Gascoyne Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study J Clin Oncol 27 2009 1607 1614
7. L. Vidal, A. Gafter-Gvili, L. Leibovici Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials J Natl Cancer Inst 101 2009 248 255
8. L. Vidal, A. Gafter-Gvili, G. Salles Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials J Natl Cancer Inst 103 2011 1799 1806
9. W.T. Swenson, J.E. Wooldridge, C.F. Lynch Improved survival of follicular lymphoma patients in the United States J Clin Oncol 23 2005 5019 5026 (Pubitemid 46224008)
10. D. Pulte, A. Gondos, H. Brenner Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century Arch Intern Med 168 2008 469 476 (Pubitemid 351559319)
11. T.J. Schneider, A. Rosta, H. Losonczy Results of the interim analysis of the 'HUSOM' trial: Hungarian study of maintenance after rituximab pretreatment, a multicentre, phase III, open-label study evaluating the benefit of a long-term MabThera (rituximab) maintenance therapy in patients with advance follicular lymphoma after induction of response (CR(u) or PR) with a MabThera (rituximab)-containing first line regimen ASH Annual Meeting Abstracts 118 2011 2714
12. M.H. van Oers, R. Klasa, R.E. Marcus Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood 108 2006 3295 3301 (Pubitemid 44794222)
13. G. Martinelli, S.F. Schmitz, U. Utiger Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98 J Clin Oncol 28 2010 4480 4484
14. B.S. Kahl, M.E. Williams, F. Hong Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT) ASH Annual Meeting Abstracts 110 2007 3420
15. B.S. Kahl, F. Hong, M.E. Williams Results of Eastern Cooperative Oncology Group Protocol E4402 RESORT: a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma ASH Annual Meeting Abstracts 118 2011 LBA-6
16. C.J. Taverna, S. Bassi, F. Hitz Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03 ASH Annual Meeting Abstracts 116 2010 1802
17. M. Rummel Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice J Natl Compr Cancer Netw 8 2010 S1 S14
18. R. Foa, A. Di Rocco, G. van Hazel Maintenance rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: updated results from the phase IIIb MAXIMA study ASH Annual Meeting Abstracts 116 2010 3945
19. M. Witzens-Harig, M. Reiz, C. Heiss Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial Ann Hematol 88 2009 51 57
20. K. Papadakis, G.A. Follows, J. Boyer Cost effectiveness analysis of rituximab maintenance in patients with untreated high tumour burden follicular lymphoma after response to immunochemotherapy: a UK national healthcare services perspective ASH Annual Meeting Abstracts 116 2010 3833
21. F. Kasteng, M. Erlanson, H. Hagberg Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden Acta Oncol 47 2008 1029 1036
22. E. Deconinck, H. Miadi-Fargier, C.L. Pen Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation Pharmacoeconomics 28 2010 35 46